Cancer Chemoresistance and Its Mechanisms: Associated Molecular Factors and Its Regulatory Role

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2023 Aug 7

PMID 37550533

Authors

Sandra Kannampuzha

Abilash Valsala Gopalakrishnan

Affiliations

Soon will be listed here.

Abstract

Cancer therapy has advanced from tradition chemotherapy methods to targeted therapy, novel drug delivery mechanisms, combination therapies etc. Although several novel chemotherapy strategies have been introduced, chemoresistance still remains as one of the major barriers in cancer treatments. Chemoresistance can lead to relapse and hinder the development of improved clinical results for cancer patients, and this continues to be the major hurdle in cancer therapy. Anticancer drugs acquire chemoresistance through different mechanisms. Understanding these mechanisms is crucial to overcome and increase the efficiency of the cancer therapies that are employed. The potential molecular pathways behind chemoresistance include tumor heterogeneity, elevated drug efflux, multidrug resistance, interconnected signaling pathways, and other factors. To surpass this limitation, new clinical tactics are to be introduced. This review aims to compile the most recent information on the molecular pathways that regulate chemoresistance in cancers, which will aid in development of new therapeutic targets and strategies.

Citing Articles

An Investigation of the Anticancer Mechanism of L. Extract Against Colorectal Cancer by Integrating a Network Pharmacological Analysis and Experimental Validation.

Jeong M, Chun J, Park S, Yeo H, Na S, Ha I Plants (Basel). 2025; 14(2.

PMID: 39861616 PMC: 11768342. DOI: 10.3390/plants14020263.

Canonical and noncanonical NOTCH signaling in the nongenetic resistance of cancer: distinct and concerted control.

Huang X, Chen W, Wang Y, Shytikov D, Wang Y, Zhu W Front Med. 2025; 19(1):23-52.

PMID: 39745621 DOI: 10.1007/s11684-024-1107-1.

Sustainable Nanomedicine: Enhancement of Asplatin's Cytotoxicity In Vitro and In Vivo Using Green-Synthesized Zinc Oxide Nanoparticles Formed via Microwave-Assisted and Gambogic Acid-Mediated Processes.

Hassan H, Sedky N, Nafie M, Mahdy N, Fawzy I, Fayed T Molecules. 2024; 29(22).

PMID: 39598716 PMC: 11596978. DOI: 10.3390/molecules29225327.

LINC01089 in cancer: multifunctional roles and therapeutic implications.

Yi Q, Zhu G, Ouyang X, Zhu W, Zhong K, Chen Z J Transl Med. 2024; 22(1):858.

PMID: 39334363 PMC: 11429488. DOI: 10.1186/s12967-024-05693-8.

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.

Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S Signal Transduct Target Ther. 2024; 9(1):128.

PMID: 38797752 PMC: 11128457. DOI: 10.1038/s41392-024-01828-x.

References

Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R . The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020; 21(8):1023-1034. PMC: 7417808. DOI: 10.1016/S1470-2045(20)30388-0. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Lippert T, Ruoff H, Volm M . Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 2008; 58(6):261-4. DOI: 10.1055/s-0031-1296504. View

Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C . Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. Front Oncol. 2022; 12:951864. PMC: 9428469. DOI: 10.3389/fonc.2022.951864. View

Jin P, Jiang J, Zhou L, Huang Z, Nice E, Huang C . Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol. 2022; 15(1):97. PMC: 9290242. DOI: 10.1186/s13045-022-01313-4. View

Tian W, Lei N, Zhou J, Chen M, Guo R, Qin B . Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death Dis. 2022; 13(1):64. PMC: 8766448. DOI: 10.1038/s41419-022-04510-8. View

Chung A, Anand K, Anselme A, Chan A, Gupta N, Venta L . A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021; 13(624):eabj5070. DOI: 10.1126/scitranslmed.abj5070. View

Pan S, Li Z, He Z, Qiu J, Zhou S . Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016; 43(8):723-37. DOI: 10.1111/1440-1681.12581. View

Dexter D, Leith J . Tumor heterogeneity and drug resistance. J Clin Oncol. 1986; 4(2):244-57. DOI: 10.1200/JCO.1986.4.2.244. View

10.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

11.

Lim Z, Ma P . Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019; 12(1):134. PMC: 6902404. DOI: 10.1186/s13045-019-0818-2. View

12.

McDonald K, Kawaguchi T, Qi Q, Peng X, Asaoka M, Young J . Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients. Ann Surg Oncol. 2019; 26(7):2191-2199. PMC: 6545241. DOI: 10.1245/s10434-019-07338-3. View

13.

Patch A, Christie E, Etemadmoghadam D, Garsed D, George J, Fereday S . Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 527(7578):398. DOI: 10.1038/nature15716. View

14.

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N . Drug resistance in cancer: an overview. Cancers (Basel). 2014; 6(3):1769-92. PMC: 4190567. DOI: 10.3390/cancers6031769. View

15.

Kumar G, Surapaneni S . Role of drug metabolism in drug discovery and development. Med Res Rev. 2001; 21(5):397-411. DOI: 10.1002/med.1016. View

16.

Sanchez-Gomez F, Diez-Dacal B, Garcia-Martin E, Agundez J, Pajares M, Perez-Sala D . Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase. Front Pharmacol. 2016; 7:237. PMC: 4973429. DOI: 10.3389/fphar.2016.00237. View

17.

Fiander H, Schneider H . Dietary ortho phenols that induce glutathione S-transferase and increase the resistance of cells to hydrogen peroxide are potential cancer chemopreventives that act by two mechanisms: the alleviation of oxidative stress and the detoxification of.... Cancer Lett. 2000; 156(2):117-24. DOI: 10.1016/s0304-3835(00)00368-2. View

18.

Welters M, Baan R, Flens M, Scheper R, Braakhuis B . Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines. Br J Cancer. 1998; 77(4):556-61. PMC: 2149938. DOI: 10.1038/bjc.1998.90. View

19.

Brozovic A, Ambriovic-Ristov A, Osmak M . The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol. 2010; 40(4):347-59. DOI: 10.3109/10408441003601836. View

20.

Byun S, Kim S, Choi H, Lee C, Lee E . Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int. 2005; 95(7):1086-90. DOI: 10.1111/j.1464-410X.2005.05472.x. View